BeiGene Enters Agreement With Novartis To Regain Worldwide Rights To Develop, Manufacture, And Commercialize TEVIMBRA (Tislelizumab)
Portfolio Pulse from Benzinga Newsdesk
BeiGene has entered an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA (Tislelizumab). The previous collaboration and license agreement from January 2021 has been terminated, and BeiGene now has full global rights to TEVIMBRA without any royalty payments due to Novartis.
September 19, 2023 | 10:01 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novartis has lost the royalty payments from BeiGene for TEVIMBRA, which could potentially decrease its revenues.
Novartis losing the royalty payments from BeiGene for TEVIMBRA means it could potentially see a decrease in its revenues in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
BeiGene regains full global rights to TEVIMBRA, which could potentially increase its revenues and profitability.
BeiGene regaining full global rights to TEVIMBRA means it can develop, manufacture, and commercialize the drug without any royalty payments to Novartis. This could potentially increase BeiGene's revenues and profitability in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100